CR11101A - Azetidinas - Google Patents

Azetidinas

Info

Publication number
CR11101A
CR11101A CR11101A CR11101A CR11101A CR 11101 A CR11101 A CR 11101A CR 11101 A CR11101 A CR 11101A CR 11101 A CR11101 A CR 11101A CR 11101 A CR11101 A CR 11101A
Authority
CR
Costa Rica
Prior art keywords
medicine
antagonist
azetidins
azetidines
leiomyomas
Prior art date
Application number
CR11101A
Other languages
English (en)
Inventor
Kevin Neil Dack
Siew Kuen Yeap
Sarah Elizabeth Skerrat
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of CR11101A publication Critical patent/CR11101A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invencion se refiere a una clase de azetidinas antagonistas de EP2 de formula general (I) en la que las variables y sustituyentes son como se definen en este documento, y especialmente a compuestos antagonistas de EP2, a su uso en medicina, particularmente en el tratamiento de endometriosis y/o miomas uterinos (leiomiomas) y a productos intermedios utiles en su sintesisy a composiciones que los contienen.
CR11101A 2007-05-10 2009-11-09 Azetidinas CR11101A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91708107P 2007-05-10 2007-05-10
US1303007P 2007-12-12 2007-12-12

Publications (1)

Publication Number Publication Date
CR11101A true CR11101A (es) 2009-12-04

Family

ID=39739736

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11101A CR11101A (es) 2007-05-10 2009-11-09 Azetidinas

Country Status (27)

Country Link
US (1) US20080280877A1 (es)
EP (1) EP2155666A1 (es)
JP (1) JP2010526801A (es)
KR (1) KR20100009582A (es)
CN (1) CN101679235A (es)
AP (1) AP2009005047A0 (es)
AR (1) AR066524A1 (es)
AU (1) AU2008249744A1 (es)
BR (1) BRPI0811444A2 (es)
CA (1) CA2686517A1 (es)
CL (1) CL2008001305A1 (es)
CO (1) CO6260066A2 (es)
CR (1) CR11101A (es)
DO (1) DOP2009000256A (es)
EA (1) EA200901381A1 (es)
EC (1) ECSP099727A (es)
GT (1) GT200900293A (es)
IL (1) IL201874A0 (es)
MA (1) MA31366B1 (es)
MX (1) MX2009011998A (es)
PA (1) PA8779601A1 (es)
PE (1) PE20090282A1 (es)
SV (1) SV2009003407A (es)
TN (1) TN2009000470A1 (es)
TW (1) TW200904409A (es)
UY (1) UY31070A1 (es)
WO (1) WO2008139287A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2222665A1 (en) * 2007-11-15 2010-09-01 Pfizer Limited Azetidines as ep2 antagonists
CN102209710A (zh) 2008-11-10 2011-10-05 辉瑞股份有限公司 吡咯烷类化合物
US20100256385A1 (en) * 2009-04-02 2010-10-07 Allergan, Inc. Prostaglandin e receptor antagonists
DE102009049662A1 (de) 2009-10-13 2011-04-14 Bayer Schering Pharma Aktiengesellschaft 2,5-Disubstituierte 2H-Indazole als EP2-Rezeptor-Antagonisten
JP6263469B2 (ja) 2011-07-15 2018-01-17 ノバルティス アーゲー アザ二環式ジ−アリールエーテルの塩およびその製造方法またはその前駆体の製造方法
TW201326154A (zh) 2011-11-28 2013-07-01 拜耳知識產權公司 作為ｅｐ２受體拮抗劑之新穎２ｈ－吲唑
EP3237401B1 (en) 2014-12-22 2019-03-06 Pfizer Inc Antagonists of prostaglandin ep3 receptor
CN110041269A (zh) * 2019-05-16 2019-07-23 海门瑞一医药科技有限公司 一种2-氯-5-羟基嘧啶的制备方法
WO2022272062A1 (en) * 2021-06-24 2022-12-29 Reservoir Neuroscience, Inc. Ep2 antagonist compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8300860D0 (en) * 1983-01-13 1983-02-16 Shell Int Research Azetidine compounds
GB8415614D0 (en) * 1984-06-19 1984-07-25 Shell Int Research Azetidine derivatives
GB8509746D0 (en) * 1985-04-16 1985-05-22 Shell Int Research Preparing azetidine derivatives
AR037364A1 (es) 2001-11-16 2004-11-03 Schering Corp Azetidinil diaminas utiles como ligandos del receptor de nociceptina orl-1
BRPI0617165B1 (pt) * 2005-10-07 2023-10-03 Exelixis Inc Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos
US8383660B2 (en) * 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives

Also Published As

Publication number Publication date
BRPI0811444A2 (pt) 2014-10-29
MX2009011998A (es) 2009-11-19
EA200901381A1 (ru) 2010-06-30
IL201874A0 (en) 2010-06-16
SV2009003407A (es) 2010-01-12
EP2155666A1 (en) 2010-02-24
UY31070A1 (es) 2009-01-05
AR066524A1 (es) 2009-08-26
PA8779601A1 (es) 2009-01-23
AU2008249744A1 (en) 2008-11-20
ECSP099727A (es) 2009-12-28
GT200900293A (es) 2010-05-17
WO2008139287A1 (en) 2008-11-20
DOP2009000256A (es) 2009-11-30
MA31366B1 (fr) 2010-05-03
CL2008001305A1 (es) 2008-07-18
AP2009005047A0 (en) 2009-12-31
CA2686517A1 (en) 2008-11-20
CO6260066A2 (es) 2011-03-22
TW200904409A (en) 2009-02-01
US20080280877A1 (en) 2008-11-13
CN101679235A (zh) 2010-03-24
KR20100009582A (ko) 2010-01-27
TN2009000470A1 (fr) 2011-03-31
PE20090282A1 (es) 2009-03-27
JP2010526801A (ja) 2010-08-05

Similar Documents

Publication Publication Date Title
CR11101A (es) Azetidinas
CU20180145A7 (es) Compuestos derivados (piperidin-1-il)(piperidin-4-il) metanona, método de preparación de los mismos y composiciones farmacéuticas que los contienen
CR11491A (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa
CR10219A (es) Piperidinoil pirrolidinas agonistas del receptor de melanocrotina tipo 4.
ECSP14013245A (es) Nuevos derivados dihidroquinolina-2-ona
EA201070912A1 (ru) Производные оксима в качестве ингибиторов hsp90
ECSP11010880A (es) Compuestos orgánicos
UY29963A1 (es) Compuestos terapéuticos: piridinas y pirazinas como andamios
CU20110235A7 (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
ECSP066375A (es) Forma cristalina gamma de clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmacéuticas que la contienen
CY1118093T1 (el) Φαρμακοτεχνικες μορφες που περιλαμβανουν παραγωγα 1-(bhta-d-γλυκοπυρανοζυλ)-2-θειενυλμεθυλβενζολιου ως αναστολεις sglt
ECSP066376A (es) FORMA CRISTALINA GAMMA-d DEL CLORHIDRATO DE IVABRADINA, SU PROCEDIMIENTO DE PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LA CONTIENEN
BR112012026004A2 (pt) derivados de ariletinila
EA201001682A1 (ru) Производные фенил- и бензодиоксинилзамещенных индазолов
SV2010003502A (es) Fungicidas novedosos
CY1114689T1 (el) C7-φθορο υποκατεστημενες ενωσεις τετρακυκλινης
SV2011003800A (es) Derivados de piridino-piridinonas, su preparacion y su aplicacion en terapeutica
CR20110381A (es) Antagonistas de 4-azetidinil-1-heteroaril-ciclohexanol de ccr2
AR061727A1 (es) Sintesis de dietil [[ 5- ( 3-fluorofenil) -piridin -2il] metil] fosfonato
CR11273A (es) Derivados-2-ona disustituidos en 3, su preparacion y su aplicacion en terapeutica
SV2010003725A (es) Nueva clase de espiro piperidinas para el tratamiento de enfermedades neurodegenerativas
EA200801549A1 (ru) Новые производные фенантридина в качестве антагонистов брадикинина
EA201170997A1 (ru) Производные индола в качестве противораковых агентов
UY33528A (es) Derivados de oxadiazoles y de piridazinas, su preparacion y su aplicacion en terapeutica

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)